Yilifang Biotech.
Shenzhen Yilifang Biotechnology Co., Ltd. was established in 2013. It is a national high-tech enterprise integrating the development, production and sales of precision medical in vitro diagnostic reagents. The companychr(34)s research and development team consist of scientific researchers from top international institutions and domestic translation medical elites, including high-quality talents of national leading talents, Class B peacock talents, and reserve talents. Targeting existing "pain points" in the market, Yilifang links with domestic and foreign cutting-edge technologies and committed to creating good products that can truly address the demands form the market.

Product architecture
From the major diseases that the society needs to solve urgently, Yilifang has built products in four major sectors. It has successfully developed more than 20 Class III in vitro diagnostic products, and its products have gradually entered the national registration stage.

Yilifang was established in the new era of precision medicine. Since its inception, Yilifang has been pragmatic and prudent in its work style. It has vigorously coordinated development in talent cultivation, research and development innovation, safety compliance, and quality system construction, etc. It has also made initial achievements. In terms of talent training, a high-quality elite team has been created. Among the current members, about 50% of employees have masterchr(34)s degrees, and more than 10% have doctoral degrees. A platform, a post-doctoral practice and innovation base, for sustainably meeting the needs of high-end talents-a postdoctoral practice innovation base has been established. On the other hand, Yilifang adheres to the idea of quality as the basis and regulations as the norm, and has established a comprehensive system in terms of quality and safety, fire safety and environmental protection. In terms of technological innovation, Yilifang has obtained national, provincial, and municipal department’ recognition and awards at various levels through independent research and development. In 2017, as the only representative of the Shenzhen In vitro Diagnostic Reagent Enterprise Group, it was promoted to the National Innovation and Entrepreneurship Competition.